As expected, downregulation of SCN5A in ischemic cardiomyopathy was associated with increased arrhythmic risk, and miR-448 inhibition could restore Nav1.5 levels and reduce arrhythmic risk. This evidence concerns the gene SCN5A and ischemic cardiomyopathy.